The global colorectal cancer therapeutics market was valued at US$ 10.73 Billion in 2020 and is projected to reach US$ 19.89 Billion by 2028; registering a CAGR of 8.1% during the forecast period 2021- 2028.
Cancer that occurs inside the colon or rectum is termed colorectal cancer or colon cancer. The Rectum is the narrow passage connecting the colon and anus. Colorectal cancer is a tumor that occurs on the inner wall of the large intestine.
The incidence of life-threatening diseases has increased globally. WHO predicts nearly 70% of the increase in colorectal cancer cases is expected by 2030. People with obesity, smoking or drinking habits, and consuming improper nutrition are at risk of developing colorectal cancer. Symptoms of colorectal cancer consist of diarrhea or constipation, fatigue, weakness, red blood stool, cramps, loss of weight, abdominal pain, bloating, and change in bowel movements. Increased awareness concerning colorectal cancer and its treatments via therapeutics and increasing casualty rates anticipates the growth of the global colorectal cancer therapeutics market. Research and development (R&D) innovations for the development of advanced drugs for the treatment of colorectal cancer. Numerous therapeutics have been launched till now and out show positive accomplishment rates. Several key players are available in the market and demand for cheaper generics in chemotherapy, care of colorectal cancer patients and awareness for its treatment is further predictable in the overall market growth during the forecast period.
The Global Colorectal Cancer Therapeutics Market report analysis is segmented by therapy, cancer type, diagnostics techniques, distribution channel, and geography. By therapy, it is categorized into immunotherapy, targeted therapy, chemotherapy, and others. Based on cancer type, the report categorizes into gastrointestinal carcinoid tumors, colorectal adenocarcinoma, and others. By diagnostics techniques, the colorectal cancer therapeutics market is categorized into colonoscopy, flexible sigmoidoscopy, stool tests, immunohistochemistry, and other diagnostics techniques. Distribution channel bifurcates into retail pharmacies, hospital pharmacies, online pharmacies, and others. Based on regional insights, the report is classified into North America (U.S, Canada), Europe (Germany, France, UK, Russia, Spain, Rest of Europe), Asia Pacific (China, Japan, India, South Korea, Rest of Asia Pacific), Rest of the World (Latin America and the Middle East & Africa).
Prominent players inducing the Global Colorectal Cancer Therapeutics Market are Novartis AG, Genentech Inc., Pfizer Inc., Teva Pharmaceutical Industries Ltd., Sanofi, Taiho Pharmaceutical, Regeneron Pharmaceuticals Inc., Ipsen Biopharmaceuticals Inc., Eli Lily and Company, Bristol Myers Squibb, Merck Sharp & Dohme Corp., and Bayer AG among others.
North America is exhibiting the highest share and is accountable for the highest growth owing to the rise in colorectal cancer. Newer product launches owing to the rising prevalence of colorectal cancer would expect market growth in the region. Moreover, rising research and development, increasing awareness and advanced diagnostics for cancer prevention are expected to augment the market growth during the forecast period.
The Asia Pacific is expected to garner the highest growth owing to increasing disposable incomes, a huge population base, and improved healthcare facilities in the region during the forecast period.
Segmentation and Scope of the Global Colorectal Cancer Therapeutics Market
The Global Colorectal Cancer Therapeutics Market is segmented by therapy, cancer type, diagnostics techniques, distribution channel, and geography.
By Cancer Type
By Diagnostics Techniques
By Distribution Channel
Rest of World
Middle East & Africa
Prominent players in the Global Colorectal Cancer Therapeutics Market